Rapt Therapeutics Inc (RAPT) Return on Equity ROE from the third quarter 2025 to third quarter 2024 and annually, average high and low, overall ranking from Sep 30 2025 to Sep 30 2024 - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Rapt Therapeutics Inc   (NASDAQ: RAPT)

Rapt Therapeutics Inc 's ROE per quarter

Return on Equity, Quarterly Results, Trends, Rankings, Statistics


What is ROE for Rapt Therapeutics Inc in the third quarter 2025?
Rapt Therapeutics Inc recorded a cumulative net loss of $-106 million during 12 months ending in the third quarter 2025, resulting in a negative return on equity (ROE) of -61.81%.

Within the Major Pharmaceutical Preparations industry 196 other companies had a higher return on equity. While return on equity, the total ranking has deteriorated compared to the second quarter 2025 from 2860 to 3341.

What is ROE?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Equity (Sep 30 2025)
III. Quarter		 (Jun 30 2025)
II. Quarter		 (Mar 31 2025)
I. Quarter		 (Dec 31 2024)
IV. Quarter		 (Sep 30 2024)
III. Quarter
Y / Y Equity Change 59.13 % 50.53 % 35.57 % 29.16 % -
Y / Y Net Income Change - - - - -
Net Income (TTM) in Millions -106 -106 -117 -130 -107
Return On Equity (TTM) -61.81 % -67.91 % -81.47 % -98.86 % -89.09 %
RAPT's Total Ranking # 3341 # 2860 # 2577 # 3348 # 2862
Equity (TTM) in Millions 152 164 177 190 96
Seq. Equity Change -7.56 % -7.31 % -6.6 % 98.84 % -12.56 %
Seq. Net Income Change - - - - -

Back to RAPT Management Effectiveness >> RAPT's 5 Years Annual ROE >> Compare RAPT ROE to its Competitors
Return On Equity Company Ranking
Within: No.
Industry # 197
Sector # 458
Overall # 3341

Return On Equity Statistics
High Average Low
-27.59 %
-55.78 %
-98.86 %
(Sep 30 2020)   (Dec 31 2024)





RAPT Annual Return On Equity (Dec 31 2024)
2024		 (Dec 31 2023)
2023		 (Dec 31 2022)
2022		 (Dec 31 2021)
2021		 (Dec 31 2020)
2020
Total Equity in Millions 190 147 245 186 104
Y / Y Equity Change 29.16 % -40.03 % 31.54 % 78.9 % 42.47 %
Net Income in Millions -130 -117 -84 -69 -53
Y / Y Net Income Change - - - - -
Return On Equity -68.38 % -79.44 % -34.2 % -37.13 % -50.77 %

Back to RAPT Management Effectiveness >> RAPT's 5 Years Annual ROE >> Compare RAPT ROE to its Competitors




More Return On Equity Ratios
Major Pharmaceutical Preparations Industry Roe Trends and Statistics
Healthcare Sector Return On Equity Statistics
RAPT's' Return on Equity at Yahoo Finance
RAPT's Roe Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Equity
Lowest Ranking Return On Equity
Subscribers only: Roe for RAPT's Competitors
Subscribers only: Roe for Rapt Therapeutics Inc 's Suppliers
Subscribers only: Return On Equity for RAPT's Customers




Companies with similar Return On Equity at Sep 30 2025, within Healthcare Sector ROE

Date modified: 2026-08-29T17:41:26+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.